We’re raising awareness for #biosimilars and the important role they play in expanding access to care in healthcare systems around the globe. At Teva, we believe that unlocking value in biologics is essential, and that value creation is the key to broadening patient access and lowering system costs around the globe. Together we can make a difference in the lives of patients through policies that support #biosimilar adoption and education. Discover the magic of biosimilars here. https://lnkd.in/dBvZfHyc #biosimilars #TevaBiosimilarsUnlockingValue #Tevapharm
sayali wadke’s Post
More Relevant Posts
-
More exciting news from my team!
We’re excited to share that AB-1005, which is being developed for moderate Parkinson’s disease, received US FDA Fast Track and UK MHRA Innovation Passport designations. There's a huge unmet need for #Parkinson's treatment, and these designations take us another step closer to accelerating access for patients. We at #AskBio, alongside Bayer | Pharmaceuticals, are dedicated to providing patients with innovative therapies and, most importantly, improving patient outcomes. #genetherapy For Medical Media – Read our press release here: https://lnkd.in/g7Mr854f
-
-
What are the biggest challenges in health care, prevention, and treatment of patients in Poland? How does one of the leading biopharmaceutical companies intend to develop in Poland? How do we cooperate with the Polish healthcare system? Watch more in the interview for Rzeczpospolita with Justin Gandy, Managing Director #MSDPolska, where he reflects on the MSD Polska key focus areas and key partnerships for a healthier future of Polish patients. LEARN MORE ➡️ https://bit.ly/3SCiEiU #MSD #MSDPoland #MSDEurope #Futureofhealth #NIO #WUM #StrategicPartnership #MedicalResearch #InnovationsInHealth #PublicPrivatePartnership
-
-
Accelerating Healthcare Innovation: FDA’s Fast-Track Programs The FDA offers several programs to speed up the development and review of drugs for serious conditions: 1. Fast Track: Speeds up development/review for drugs addressing unmet needs. 2. Breakthrough Therapy: For drugs showing major improvement over existing treatments. 3. Accelerated Approval: Early approval based on surrogate/intermediate endpoints. 4. Priority Review: Cuts review time from 10 to 6 months for significant advancements. 5. Priority Review Voucher: Rewards development of drugs for rare diseases. These programs help bring new treatments to patients faster. #FDA #FastTrack #BreakthroughTherapy #AcceleratedApproval #PriorityReview #HealthcareInnovation #Pharma #Biotech #MedicalResearch #PatientCare
-
Parkinson & Movement Disorders Physiotherapist Specialist | PhD | Parkinson Researcher
What is needed to improve the transfer of ideas from bench to bedside, to provide more effective treatments for "patients" in need? How can stakeholders in the healthcare ecosystem—including patient groups, scientists, investors, the pharmaceutical industry and med-tech innovators—collaborate to improve and accelerate processes in the search for better outcomes, and even cures? From bench to bedside—accelerating progress in healthcare innovations | Feb 7th 2024 | https://lnkd.in/dzpTZSwm Parkinson's Europe
-
-
The Inflation Reduction Act will increase drug affordability—but that money comes from somewhere. Ryan Cox, VP, Director, PRECISIONvalue Access Experience Team, discusses the unintended consequences for payers, biopharmaceuticals—and the future of patient’s drug choices. View now. #pharmamarketing #marketaccess #inflationreductionact #Access90 #biopharmaceuticals
-
Recognizing the Importance of Patient Input in Clinical Trials Savvy partnered with a global biopharmaceutical company to agilely gather patient insights and integrate them into protocol designs during their trial development. This work enabled them to effectively mitigate risks and challenges related to recruitment, retention, and data collection. Learn how Savvy helps companies garner vital patient insights: https://hubs.ly/Q02wyg3m0 To schedule time with Kelly Franchetti RN,CCRN,CEN to talk more in-depth: https://hubs.ly/Q02wyhFs0 #askpatients #healthcare #clinicalresearch #trial #trialdesigns #patientinsights
-
-
How can we spread, scale & sustain life-saving treatments for disease? Moving #evidencebased therapies for cardiovascular-kidney-metabolic (#CKM) into action could be easier if partners come together. Read about what clinical researchers, payers, funders, journal editors, association, quality, and pharmaceutical industry leaders had to say about #knowledgetranslation at the DCRI’s #Implementation Summit. https://duke.is/imp-summit
-
-
SURVEY: 47 percent of #payers, #IDNs, and other stakeholders plan to execute a prescription digital therapeutics strategy by 2025, according to our Second Annual Market Access Survey. In addition, 40 percent of respondents say they will execute #AI plans by 2025 for administrative and manual functions, including streamlining #priorauthorization. “Organizations desire additional clarity regarding the value of prescription therapeutics and reimbursement,” said Valuate Principal Tony Gibson. “CMS and FDA activity in this area will also spur payer planning in this area.” #marketaccess #pharma #biotech
-
-
Read an insightful #AuthoredArticle by Sidharth Srinivasan, CEO, Lupin Digital Health, emphasizing how digital therapeutics empower women to take an active role in managing their cardiac health, allowing for personalized interventions and treatment plans that align with their specific needs. To read, visit: https://bit.ly/3TyHscc #Lupin #Pharmaceuticals #DigitalTherapeutics #BreakingBarriers #CardiacHealth #OverallWellbeing #WomensHealth
-
-
Regulators are accelerating approval paths for biosimilars, but require clinical trials in patients. With 80+ biosimilar studies delivered across multiple therapeutic areas since 2009, partnering with IQVIA can help you to understand the biologics landscape, drive patient enrollment, navigate regulations, and conduct flexible trials. Learn more. https://bit.ly/3U2C8yB #clinicaltrials #biosimilars
Biosimilars
iqvia.com